% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sanz:305584,
      author       = {J. Sanz and G. Bug$^*$ and F. Ciceri and C. Craddock and R.
                      Dillon and J. Esteve and M. G. D. Porta and M. Heuser and D.
                      C. de Leeuw and A. Nagler and F. Onida and G. J. Roboz and
                      A. Ruggeri and I. Sánchez-Ortega and M. Srour and I.
                      Yakoub-Agha and F. Buccisano},
      title        = {{M}easurable residual disease-guided interventions in
                      patients with acute myeloid leukaemia undergoing allogeneic
                      haematopoietic cell transplantation: best practice
                      recommendations from the {E}uropean {S}ociety for {B}lood
                      and {M}arrow {T}ransplantation {P}ractice {H}armonisation
                      and {G}uidelines {C}ommittee.},
      journal      = {The lancet / Oncology},
      volume       = {26},
      number       = {11},
      issn         = {1470-2045},
      address      = {London},
      publisher    = {The Lancet Publ. Group},
      reportid     = {DKFZ-2025-02243},
      pages        = {e586 - e596},
      year         = {2025},
      abstract     = {Measurable residual disease (MRD) is a key predictor of
                      relapse, the primary cause of treatment failure after
                      allogeneic haematopoietic cell transplantation (allo-HCT) in
                      acute myeloid leukaemia. This Policy Review, based on
                      guidance from the European Society for Blood and Marrow
                      Transplantation, provides practical recommendations for
                      incorporating MRD assessment into clinical decision making
                      during the transplantation process, the application of which
                      remains challenging in acute myeloid leukaemia due to
                      technical limitations and the limited availability of
                      standardised, evidence-based approaches. Available methods
                      include reverse transcription quantitative PCR, digital
                      droplet PCR, next-generation sequencing, and multiparametric
                      flow cytometry-chimerism-based approaches are under
                      investigation. This Policy Review highlights the importance
                      of MRD monitoring to enable timely, risk-adapted
                      interventions that encompass both pre-transplantation and
                      post-transplantation periods and can include tailoring
                      conditioning intensity, donor selection, immunosuppression
                      management, donor lymphocyte infusions, and pharmacological
                      therapies such as FLT3 or IDH inhibitors, hypomethylating
                      agents, venetoclax, or menin inhibitors. These
                      recommendations aim to harmonise MRD-driven clinical
                      practice and improve patient outcomes, while identifying key
                      areas for future research.},
      subtyp        = {Review Article},
      keywords     = {Humans / Neoplasm, Residual / Hematopoietic Stem Cell
                      Transplantation: standards / Hematopoietic Stem Cell
                      Transplantation: adverse effects / Leukemia, Myeloid, Acute:
                      therapy / Leukemia, Myeloid, Acute: pathology / Leukemia,
                      Myeloid, Acute: genetics / Transplantation, Homologous /
                      Europe / Transplantation Conditioning / Clinical
                      Decision-Making},
      cin          = {FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41167226},
      doi          = {10.1016/S1470-2045(25)00426-7},
      url          = {https://inrepo02.dkfz.de/record/305584},
}